Lipella Pharmaceuticals

A Message from Our CEO, Dr. Jonathan Kaufman The results from our?Phase 2a study of LP-310 for Oral Lichen Planus (OLP)?reinforce our commitment to developing much-needed treatment options for this underserved condition. With?statistically significant reductions in pain, ulceration, and inflammation, LP-310 continues to show strong potential as a targeted therapy for OLP. With no FDA-approved treatments available, we remain focused on advancing LP-310 and bringing relief to the millions affected by this chronic disease.

Lipella Pharmaceuticals ( $LIPO) is pleased to announce significant Phase 2a Topline Data for LP-310, our liposomal-tacrolimus oral rinse formulation of LP-10, to treat oral lichen planus (OLP). LP-310 demonstrated clinically meaningful reductions in pain, ulceration, and inflammation across all key metrics. Read more here: https://bit.ly/41arPvk #LIPO #toplinedata #LP310 #OLP

Lipella Pharmaceuticals is pleased to announce the FDA has granted approval for Expanded Access Program for LP-310 in Oral Lichen Planus (OLP). This program will allow OLP patients to access treatments outside of a clinical trial that are not yet approved by the FDA and reinforces LP-310’s potential as a new therapeutic option for OLP, supporting ongoing clinical development efforts. Read more here: https://bit.ly/3WQPIW9 #LIPO #LP310 #orallichenplanus #FDA #EAP

Lipella Pharmaceuticals (Nasdaq: LIPO) has announced a publication in?Cureus Journal of Medical Science, a peer-reviewed article highlighting the potential treatment for Oral Lichen Planus (OLP) with a focus on localized drug delivery. The paper emphasizes the potential of Lipella’s investigational therapy,?LP-310, a novel oral rinse formulation of LP-10 (tacrolimus) specifically designed to provide localized therapeutic effects for OLP while minimizing systemic exposure. Read more here:?https://bit.ly/3ZhzmX8?#LIPO #OLP #peerreview #CUREUS #LP310 #LP10

Today Lipella Pharmaceuticals has announced the completion of dosing for the first cohort in our multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). The pace of our promising progress puts us on track to deliver top-line data by year-end and complete the trial by mid-2025. Read the full release here:https://lnkd.in/eFmKtB9w #clinicaltrials #Phase2a #OLP

Lipella Pharmaceuticals $LIPO Announces Completion Of First Cohort In Phase 2a Trial Of LP-310 For Oral Lichen Planus, Advancing To Next Dose Group #stockstowatch #stocksinnews #Investors #daytrader https://lnkd.in/eXd-HHtT

Our recent patent news has been featured by BioTuesdays. “We believe our proprietary liposomal delivery platform holds significant potential to enhance efficacy and tolerability across various therapeutic areas, including oncology, cancer survivorship and immunotherapy,” stated Lipella Pharmaceuticals $LIPO ’ Chief Medical Officer, Michael Chancellor. Read the full BioTuesday report here: ?https://bit.ly/3UOoJK3 #LIPO #patents #recentnews #liposome #biotuesdays

Lipella Pharmaceuticals ($LIPO) has announced the patent for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) today. This patent covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles and extends market exclusivity for Lipella’s two lead clinical assets, LP-10 and LP-310. Read more here:?https://bit.ly/48Kb5gC?#LIPO #patents #liposome #LP10 #LP310

Lipella Pharmaceuticals (LIPO) has announced the patent for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) today. This patent covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles and extends market exclusivity for Lipella’s two lead clinical assets, LP-10 and LP-310. Read more here:?https://bit.ly/48Kb5gC? #LIPO #patents #liposome #LP10 #LP310 ?

We are pleased to announce we will be attending the 2024 Spartan Capital Investor Conference in New York that will be held?on November 4th, 2024. Lipella Pharmaceuticals $LIPO CEO Jonathan Kaufman will be presenting?at 9:25am EST?and is available for one-on-one meetings with registered investors of the conference. #LIPO #spartancapital #investorconference #presentation